2 withdrawn, 1 active not recruiting, 1 completed, 1 recruiting. 6 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Withdrawn 2, Active not recruiting 1, Completed 1, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Active not recruiting 1, Withdrawn 1 |
Follow NMO Spectrum Disorder: new trials by email Literature Review of NMO Spectrum Disorder trials Research Report on NMO Spectrum Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University General Hospital | 27 | 2025-04-10 | 2026-10-16 |
| FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack Efgartigimod Alfa Injection, High-dose intravenous methylprednisolone - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 | Unknown | Tianjin Medical University General Hospital | 63 | 2024-07-05 | 2024-07-11 |
| Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Daratumumab, Placebo - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Active not recruiting | Tianjin Medical University General Hospital | 135 | 2022-11-01 | 2025-03-30 |
| Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders Belimumab - NMO Spectrum Disorder | Phase 1 / Phase 2 | Completed | Tianjin Medical University General Hospital | 14 | 2021-12-12 | 2024-10-16 |
| Autologous Transplant To End NMO Spectrum Disorder Rituximab, Cyclophosphamide, Mesna - Neuromyelitis Optica, Devic's Disease | Phase 2 / Phase 3 | Withdrawn | Northwestern University | 2019-11-01 | 2019-11-20 |
Neuromyelitis Optica (6) · Marijuana Abuse (1) · Muscle Spasticity (1) · Myasthenia Gravis (1) · Myositis (1) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1)
Autoimmune Diseases (6) · Autoimmune Diseases of the Nervous System (6) · Cranial Nerve Diseases (6) · Demyelinating Autoimmune Diseases, CNS (6) · Demyelinating Diseases (6) · Eye Diseases (6) · Immune System Diseases (6) · Myelitis, Transverse (6) · Nervous System Diseases (6) · Optic Nerve Diseases (6) · Optic Neuritis (6) · Muscular Diseases (2) · Musculoskeletal Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Chemically-Induced Disorders (1)
Antilymphocyte Serum (1) · Cyclophosphamide (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Immunoglobulin G (1) · Immunoglobulins, Intravenous (1) · Mesna (1) · Methylprednisolone (1) · Methylprednisolone Acetate (1) · Methylprednisolone Hemisuccinate (1) · Octagam (1) · Rituximab (1) · belimumab (1) · daratumumab (1) · efgartigimod alfa (1)
Tianjin Medical University General Hospital (4) · Michael, Levy M.D.,Ph.D. (1) · Northwestern University (1)
China (3) · United States (2)
Anastasia Vishnevetsky, MD, PhD (1) · Michael Levy, MD, PhD (1) · Qiang Liu, M.D.,Ph.D (1) · Richard Burt, MD (1)